Depo-Provera Lawsuit 2026: Bone Density Loss — the Second Injury in the FDA Black Box Warning

Most Depo-Provera coverage focuses on brain tumors. But the FDA's strongest warning on the drug is a black box warning, on the label since 2004: Depo-Provera "may cause significant loss of bone mineral density" that worsens with longer use and "may not be completely reversible." In 2026, that warning is powering a second wave of claims.

Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate, given every three months. It works partly by suppressing estrogen — and because estrogen protects bone, sustained suppression slows the body's ability to rebuild bone tissue. Bone mineral density (BMD) is the measure of that bone strength, most often tested with a DEXA scan and reported as a T-score.

Key facts

  • The FDA added the black box bone-density warning to Depo-Provera's label in 2004 — the agency's most serious warning category.
  • The label warns that bone loss is greater with longer use and advises that Depo-Provera not be used for more than two years unless other contraceptive methods are inadequate.
  • Adolescents are singled out in the warning because the teen years are when women build peak bone mass — losses then may never be fully recovered.
  • The label states the loss "may not be completely reversible" even after the injections stop.
  • Separately, meningioma (brain tumor) cases against Pfizer are consolidated in MDL-3140 in the Northern District of Florida — the bone-density claims rest on a different injury and the drug's own warning.

What the black box warning actually says — and why it matters legally

Failure-to-warn cases usually involve a fight over what the manufacturer knew. Bone-density cases are different: the risk is conceded on the label itself. The legal questions are narrower and sharper. Were patients actually told? Did prescribers, working from Pfizer's marketing and representative visits, treat the two-year guidance as a soft suggestion while women stayed on the shot for five, ten or fifteen years? And were teenage users — the group the warning worries about most — counseled that they were spending down the bone mass they would need at sixty?

Plaintiffs argue the warning's existence proves the risk was real and serious, while their own records show the practical reality: repeat injections administered year after year at routine visits, with no DEXA monitoring and no documented conversation about switching methods at the two-year mark. That gap between the label and the lived experience is the heart of a bone-density claim.

The injuries women are reporting

Bone loss is silent until it isn't. The diagnoses appearing in these claims include osteopenia (bone density below normal but not yet osteoporosis) in women in their twenties and thirties, osteoporosis decades earlier than expected, stress fractures and fragility fractures — bones breaking from falls or impacts that should not have broken them — and dental and jaw complications tied to low bone density. A DEXA T-score of −1.0 to −2.5 indicates osteopenia; −2.5 or lower is osteoporosis. When a 34-year-old who used Depo for a decade presents with the T-score of a postmenopausal woman, that scan becomes the central exhibit.

How a bone-density claim is proven

The file typically rests on four pillars. Injection records from clinics, pharmacies or health departments establish duration — the label itself ties harm to length of use. DEXA scans, ideally with an earlier baseline, quantify the loss. Medical records document fractures, pain and any osteoporosis treatment. And exclusion of rival causes — eating disorders, steroid use, thyroid disease, early menopause — lets an expert attribute the deficit to estrogen suppression from the drug. Our companion guide explains how the better-known tumor claims are screened in the meningioma science behind the Depo-Provera lawsuits; bone cases follow the same records-first logic with different medical proof.

Can you pursue both claims?

Sometimes. The meningioma litigation and the bone-density claims involve different injuries, different warnings and largely different plaintiffs, but a woman who used Depo-Provera for years and suffered both a tumor diagnosis and documented bone loss should have both reviewed. More commonly, bone-density plaintiffs are women who never developed a tumor and assumed they had no case at all — the assumption this second wave of litigation is correcting. Screening starts with two questions: how long were you on the shot, and is there a DEXA scan or fracture in your records? Our Depo-Provera lawyer guide walks through the filing process and what firms look for at intake.

Deadlines and next steps

Filing deadlines run from when you knew — or reasonably should have known — that your bone loss might be connected to the drug, which for many women is the moment they first see the warning discussed publicly. Because bone loss is often discovered incidentally (a scan ordered for another reason), the discovery date in your chart matters enormously; do not assume an old diagnosis kills a claim, and do not wait, either. Compensation varies widely by case, and most settlements are confidential, so be skeptical of anyone quoting figures. What is concrete: DEXA documentation and a complete injection history are the two assets your future case will be built on, and both are worth gathering now.

For clear, short video explainers on drug-injury litigation and consumer health rights, the Problem Solved YouTube channel covers new developments as they happen.

Who Benefits From This — and Who Does Not

This bone-density guide is most useful to readers who can connect long-term Depo-Provera use to a documented bone diagnosis, because the claim rests on the drug's own black box warning, in place since 2004, rather than on a new scientific theory.

Who benefits:

  • Long-term users with a DEXA scan or fracture on record: How: gather a complete injection history, DEXA scans (ideally with an earlier baseline), and medical records of fractures or osteoporosis treatment.
  • Women who never developed a meningioma and assumed they had no case: How: screening starts with two questions — how long were you on the shot, and is there a DEXA scan or fracture in your records?
  • Teenage and young-adult users: How: the warning singles out adolescents building peak bone mass, so ask a doctor whether a scan is appropriate, especially after unexplained fractures.

Who benefits less, or not at all:

  • Anyone expecting a promised payout: Compensation varies widely by case and most settlements are confidential, so be skeptical of anyone quoting figures.
  • Readers with no testing at all: Only testing can say whether bone was damaged — a DEXA T-score of −1.0 to −2.5 indicates osteopenia and −2.5 or lower indicates osteoporosis.
  • Readers whose bone loss has a documented rival cause: Eating disorders, steroid use, thyroid disease or early menopause must be excluded before an expert can attribute the deficit to the drug.

Read more: the companion guide to the meningioma science behind the Depo-Provera lawsuits

Frequently asked questions

How do I know if Depo-Provera damaged my bones?

Only testing can say. A DEXA scan measures your bone mineral density and produces a T-score; a score between −1.0 and −2.5 indicates osteopenia and −2.5 or lower indicates osteoporosis. If you used the shot for years — especially starting as a teenager — ask your doctor whether a scan is appropriate, particularly if you have had unexplained fractures.

Is the bone loss from Depo-Provera reversible?

Partially, for many women: bone density often improves after injections stop, but the FDA label warns the loss "may not be completely reversible," and recovery tends to be slower at the hip than the spine. Adolescents may never reach the peak bone mass they would otherwise have built.

Do I need a meningioma to have a Depo-Provera case?

No. The brain-tumor cases are one category of claim. Bone-density loss is a separate injury described in the drug's own black box warning, and women with documented osteopenia, osteoporosis or fragility fractures after long-term use may qualify on that basis alone.

How long did I need to use the shot for a bone claim?

There is no universal cutoff, but the label's warning intensifies with duration and specifically cautions against use beyond two years when alternatives are adequate. Longer use — five or ten years of continuous injections — generally makes the medical attribution stronger, which is why a complete injection history is the first record firms request.

Who benefits most from this bone-density guide — and who does not?

Long-term Depo-Provera users with DEXA-documented osteopenia, osteoporosis or fragility fractures benefit most, including women who never developed a meningioma and assumed they had no case. This guide does not help anyone expecting a promised payout — compensation varies widely and most settlements are confidential — or anyone without testing, since only a DEXA scan can say whether bone was damaged.

How do I start a bone-density claim review?

Gather the two assets a future case is built on: a complete injection history and DEXA documentation, ideally with an earlier baseline, plus medical records of fractures or treatment. Then consult a qualified attorney and your physician about your specific situation, and do not wait: filing deadlines run from when you knew, or reasonably should have known, that your bone loss might be connected to the drug.

This article is general information about an ongoing litigation, not legal or medical advice. If you used Depo-Provera long-term and have been diagnosed with bone loss, consult a qualified attorney and your physician about your specific situation.

Watch on YouTube

Problem Solved on YouTube